AG
ACOR

Advisor Group’s Acorda Therapeutics ACOR Stock Holding History

Advisor Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19
Closed -$4.79K – 5500
2019
Q3 		$6K Buy
19
+8
+73% +$4.35K ﹤0.01% 4611
2019
Q2 		$10K Buy
11
+2
+22% +$2.46K ﹤0.01% 4390
2019
Q1 		$13K Buy
9
+4
+80% +$7.21K ﹤0.01% 4241
2018
Q4 		$10K Sell
5
-2
-29% -$4.35K ﹤0.01% 4220
2018
Q3 		$16K Buy
7
+5
+250% +$15.5K ﹤0.01% 4038
2018
Q2 		$7K Hold
2
– – ﹤0.01% 4275
2018
Q1 		$7K Hold
2
– – ﹤0.01% 4288
2017
Q4 		$4K Hold
2
– – ﹤0.01% 4525
2017
Q3 		$5K Buy
2
+1
+100% +$2.63K ﹤0.01% 4298
2017
Q2 		$2K Sell
1
-1
-50% -$1.98K ﹤0.01% 4549
2017
Q1 		$4K Sell
2
-1
-33% -$2.88K ﹤0.01% 4231
2016
Q4 		$6K Hold
3
– – ﹤0.01% 3871
2016
Q3 		$8K Hold
3
– – ﹤0.01% 3707
2016
Q2 		$8K Buy
+3
New +$9.76K ﹤0.01% 3600

Other funds holding ACOR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Advisor Group's ACOR Position: Q4 2019 in Review

Advisor Group sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 19 shares — an estimated $4.79K sold.

Advisor Group first reported a position in ACOR in Q2 2016 and held it in 14 quarters. The position peaked at $16K in Q3 2018. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Advisor Group reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Advisor Group sold 19 Acorda Therapeutics shares in Q4 2019, an estimated $4.79K.
  • Advisor Group first reported a position in Acorda Therapeutics in Q2 2016 and held it in 14 quarters.
  • Advisor Group's Acorda Therapeutics position peaked at $16K in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.